cerca CERCA
Martedì 27 Settembre 2022
Aggiornato: 10:55
Temi caldi

Salute_E_Benessere Chimica_E_Farmacia Economia_E_Finanza Salute_E_Benessere Chimica_E_Farmacia Economia_E_Finanza Chimica_E_Farmacia

comunicato stampa

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer. HCL has further agreed to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatmen...

ora in
Prima pagina
in Evidenza